Ruangrong Cheepsattayakorn¹, Attapon Cheepsattayakorn^2,3* and Porntep Siriwanarangsun²

¹Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10^th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.

Received: July 28, 2023; Published: August 14, 2023

Abstract

A comprehensive search was carried out in mainstream bibliographic databases or Medical Subject Headings, including ScienDirect, PubMed, Scopus, and ISI Web of Science. The search was applied to the articles that were published between 2021 and mid-2023. With strict literature search and screening processes, it yielded 7 articles from 349 articles of initial literature database. A number of previous studies demonstrated that KTRs or non-KTRs with renal failure markedly reduced vaccine response, whereas adaptive protocols of mRNA COVID-19 vaccination or alternative adjuvant vaccines is now not known yet. A recent study revealed that acute kidney injury and mortality could be caused by SARS-CoV-2 (COVID-19) around 50% and 23% of the infected KTRs.

In conclusion, among the immunocompromised population, including KTRs, DPs, PDs, at least three doses of mRNA-COVID-19 vaccination was recommended to be the preparation of choice. Withdrawal of the immunosuppressants in KTRs and immunocompromised individuals prior COVID-19 vaccination and at least third dose of mRNA-COVID-19 vaccination should be performed.

 Keywords: Cellular; Humoral; Immune; Response; Kidney; Transplant; Hemodialysis; COVID-19; Vaccine; mRNA

References

1. Rincvon-Arevalo H., et al. “Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients”. Science Immunology 60 (2021): eabj1031.
2. Stumpf J., et al. “Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients : a prospective, multicenter observational study using mRNA 1273 or BNT162b2 mRNA vaccine”. Lancet Regional Health Europe 9 (2021): 100178.
3. Chen JJ., et al. “Immunogenicity rates after SARS-CoV-2 vaccination in people with end-stage kidney disease : a systematic review and meta-analysis”. JAMA Network Open10 (2021): e2131749.
4. Strengert M., et al. “Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on hemodialysis”. EBioMedicine 70 (2021): 103524.
5. Stumpf JKA., et al. “Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and hemodialysis patients using messenger RNA”. Nephrology Dialysis Transplantation4 (2022): 796-798.
6. Mulley WR., et al. “Primary seroresponses to double-dose compared with standard-dose hepatitis B vaccination in patients with chronic kidney disease : a systematic review and meta-analysis”. Nephrology Dialysis Transplantation 32 (2017): 136-143.
7. Liao Z., et al. “Effect of a booster dose of influenza vaccine in patients with hemodialysis, peritoneal dialysis and renal transplant recipients : a systematic literature review and meta-analysis”. Human Vaccines and Immunotherapeutics 12 (2016): 2909-2915.
8. Syed-Ahmed M and Narayanan M. “Immune dysfunction and risk of infection in chronic kidney disease”. Advances in Chronic Kidney Disease 26 (2019): 8-15.
9. Kato S., et al. “Aspects of immune dysfunction in end-stage renal disease”. Clinical Journal of the American Society of Nephrology 3 (2008): 1526-1533.
10. Betjes MGH. “Immune cell dysfunction and inflammation in end-stage renal disease”. Nature Reviews Nephrology 9 (2013): 255-265.
11. Hovd M., et al. “Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic : a nationwide cohort study”. Lancet (2023): 102035.
12. Nimmo A., et al. “The global impact of COVID-19 on solid organ transplantation : two years into a pandemic”. Transplantation 7 (2022): 1312-1329.
13. Midtvedt K., et al. “Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response”. American Journal of Transplantation11 (2022): 2704-2706.
14. Kamar N., et al. “Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant”. JAMA Network Open 11 (2021): e2136030.
15. Boyarski BJ., et al. “SARS-CoV-2 messenger RNA vaccine immunogenicity in solid organ transplant recipients with prior COVID-19”. Transplantation11 (2021): e270-e271.
16. Hall VG., et al. “Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients”. The New England Journal of Medicine 13 (2021): 1244-1246.
17. Sakuraba A., et al. “A systematic review and meta-analysis of serologic response following coronavirus disease 2019 (COVID-19) vaccination in solid organ transplant recipients”. Viruses8 (2022): 1822.
18. Mahallawi WH., et al. “Decline humoral immunity of kidney transplant recipients to SARS-CoV-2 vaccines”. Infection and Drug Resistance 16 (2023): 2829-2840.
19. Graninger M., et al. “Prediction of humoral and cellular immune response to COVID-19 mRNA vaccination by TTV load in kidney transplant recipients and hemodialysis patients”. Journal of Clinical Virology 162 (2023): 105428.
20. Benning L., et al. “Humoral response to SARS-CoV-2 mRNA vaccination in previous non-responder kidney transplant recipients after short-term withdrawal of mycophenolic acid”. Frontiers in Medicine (2022).
21. de Boer SE., et al. “Enhanced humoral immune response after COVID-19 vaccination in elderly kidney transplant recipients on everonimus versus mycophenolate mofetil-containing immunosuppressive regimens”. Transplantation 8 (2022): 1615-1621.
22. Tylicki L., et al. “Boosting humoral immunity from mRNA COVID-19 vaccines in kidney transplant recipients”. Vaccines 56 (2022).

Citation

Citation: Attapon Cheepsattayakorn., et al. “Humoral and Cellular Immune Response in Kidney Transplant Recipients with COVID-19 Vaccination: A Systematic Review and Meta-Analysis". Acta Scientific Microbiology 6.9 (2023): 60-65.

Copyright

Copyright: © 2023 Attapon Cheepsattayakorn., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.